It has been decades since the concept of gene therapy emerged in the ophthalmology field.
Excitement was renewed with the 2017 approval of Luxturna (voretigene neparvovec, Spark Therapeutics) for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.
Gene therapy has also shown significant potential in ongoing clinical trials for age-related macular degeneration, geographic atrophy and diabetic retinopathy.
“The approval of Luxturna launched the ophthalmology field into looking at other indications for gene therapy to be approved. This has opened the field for a